Traders Purchase Large Volume of Citius Pharmaceuticals Call Options (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 6,590 call options on the stock. This is an increase of approximately 1,308% compared to the typical daily volume of 468 call options.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CTXR shares. EF Hutton Acquisition Co. I raised Citius Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 15th. HC Wainwright restated a "buy" rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a report on Friday, May 31st.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds have recently made changes to their positions in CTXR. BNP Paribas Financial Markets lifted its holdings in shares of Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company's stock worth $62,000 after buying an additional 32,686 shares during the period. Arkadios Wealth Advisors lifted its holdings in shares of Citius Pharmaceuticals by 50.0% in the 2nd quarter. Arkadios Wealth Advisors now owns 150,000 shares of the company's stock worth $88,000 after buying an additional 50,000 shares during the period. Wealth Advisory Solutions LLC purchased a new stake in shares of Citius Pharmaceuticals in the 1st quarter worth $135,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Citius Pharmaceuticals by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company's stock worth $6,286,000 after buying an additional 104,889 shares during the period. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Stock Up 9.4 %

CTXR traded up $0.09 during trading hours on Tuesday, reaching $1.02. 3,636,649 shares of the company's stock traded hands, compared to its average volume of 1,506,326. The firm has a 50-day moving average price of $0.71 and a 200 day moving average price of $0.73. Citius Pharmaceuticals has a 52-week low of $0.48 and a 52-week high of $1.07. The firm has a market capitalization of $184.28 million, a PE ratio of -4.29 and a beta of 1.67.

Citius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Equities analysts predict that Citius Pharmaceuticals will post -0.21 EPS for the current fiscal year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.